Implementation starts with preparing the site for the digital mammography system, including installing the tomosynthesis‑ready gantry and calibrating the automated exposure control. The Panascope team verifies detector performance with a mammography phantom to confirm that microcalcifications as small as 100 microns can be seen. The biopsy module is installed with stereotactic guidance calibrated to 0.5 mm accuracy, and the system is connected to the department’s reporting platform so that BI‑RADS coding and dose records are generated automatically.

The system supports both 2D full‑field imaging and 3D tomosynthesis. Tomosynthesis uses fifteen low‑dose projections across a fifteen‑degree arc, reducing tissue overlap by about forty percent in dense breasts. Automated exposure control uses a feedback loop that measures compression force and glandular content to choose the appropriate kVp (typically 26–32 kVp) and the correct target and filter combination such as Mo/Mo, Mo/Rh, Rh/Rh, or Rh/Ag. This keeps the average glandular dose below 3.0 mGy per view. High‑volume screening sites may add a dedicated prone biopsy table to separate biopsy procedures from screening rooms, increasing screening throughput by roughly thirty percent.

The biopsy package includes guides for needles ranging from 14‑gauge to 9‑gauge. The 9‑gauge vacuum‑assisted option is selected for centers that perform many diagnostic biopsies, as the larger sample size helps reduce the false‑negative rate to below two percent. Dose tracking records glandular dose for each exposure and generates cumulative summaries, with alerts when a patient’s five‑year cumulative dose exceeds 30 mGy.

Implementation of the 1.5‑tesla helium‑free MRI system begins with planning for the sealed‑loop cryocooler, which removes the need for routine helium refills. The Panascope team installs the dedicated 16‑channel bilateral breast coil and calibrates its anterior–posterior compression mechanism to ensure consistent patient positioning. The breast imaging software is set up with dynamic contrast‑enhanced sequences that achieve a temporal resolution of under ten seconds per phase, supporting detailed kinetic analysis. Whole‑body gynecologic protocols for uterine, ovarian, and rectal cancer staging are preloaded as part of the configuration.

The helium‑free design uses a cryocooler that recondenses helium vapor, lowering annual operating costs by an estimated thirty to fifty thousand dollars compared with traditional systems. The 16‑channel breast coil supports simultaneous bilateral imaging with 0.8‑mm³ isotropic resolution, reducing total exam time from about forty‑five minutes to thirty minutes. For MR‑guided breast biopsy, a dedicated grid with five‑millimeter spacing in both the medial–lateral and cranial–caudal directions is installed, along with an aspiration system that works with the breast coil.

Dynamic contrast‑enhanced imaging is configured with an injection protocol of 0.1 mmol per kilogram of gadolinium at two milliliters per second, followed by a twenty‑milliliter saline flush. Automated kinetic analysis classifies lesions into BI‑RADS categories based on enhancement and washout behavior, with reported specificity around eighty‑five percent when combined with morphological assessment. Volumetric tools are enabled to track tumor response during neoadjuvant therapy, where a thirty‑percent reduction in volume after two treatment cycles is associated with an approximately eighty‑percent likelihood of achieving a complete pathological response.

Implementation focuses on configuring the cart‑based ultrasound system with transducers and software packages designed for women’s health. Panascope installs a high‑frequency linear transducer (6–18 MHz) equipped with an integrated needle‑guidance feature, calibrating the on‑screen trajectory so that the projected path and depth markers match the actual needle position. An endocavitary transducer with a 180‑degree field of view is added for gynecologic imaging, and both elastography and contrast‑enhanced ultrasound functions are activated.

The 6–18 MHz linear probe provides roughly thirty percent higher near‑field resolution than standard 5–12 MHz probes, allowing the needle tip to be visualized within about 2 mm of the skin surface—important for targeting superficial breast lesions. Strain elastography is set up with a color scale from blue (soft) to red (firm), using a stiffness‑ratio threshold of 4:1 for characterizing thyroid and breast nodules. The endocavitary probe uses disposable sterile covers under fifty microns thick to maintain acoustic transparency while supporting infection‑control requirements.

Contrast‑enhanced ultrasound is configured with a low mechanical index below 0.2 to preserve microbubble stability. The contrast‑specific imaging mode is set to a minimum of fifteen frames per second to capture early arterial‑phase enhancement. A biopsy bracket compatible with 14‑gauge through 18‑gauge needles is installed, with the 14‑gauge option preferred when core samples must retain architectural detail.

Panascope standardizes contrast‑enhanced workflows by configuring unified administration protocols for both MRI and ultrasound. The 1.5‑tesla helium‑free MRI system and the cart‑based ultrasound unit are set up with contrast‑tracking modules that record injection details and enhancement behavior. MRI kinetic‑analysis results are linked to the reporting platform so that BI‑RADS descriptors populate automatically, while the ultrasound system is configured with a dual‑display layout that shows contrast and grayscale images side by side.

For MRI, the contrast protocol is set at 0.1 mmol per kilogram delivered at 2 mL per second, with a programmable delay aligned to the start of the dynamic sequence. Volumetric tools calculate lesion size, enhancement ratios, and time‑to‑peak values, and these measurements are displayed with color‑coded kinetic curves. For ultrasound, sulfur‑hexafluoride microbubbles are used as the contrast agent, with a 2.4 mL dose followed by a 10 mL saline flush. The contrast‑specific mode is configured with a low mechanical index below 0.2 to maintain microbubble stability throughout the five‑minute observation period.

The integrated workflow enables direct comparison of MRI and ultrasound contrast findings, which is especially useful for lesions that remain uncertain after initial imaging. For patients receiving neoadjuvant therapy, mid‑treatment contrast‑enhanced ultrasound is configured to assess treatment response, with sensitivity around ninety percent for identifying residual disease.

Panascope configures its radiation‑safety workflow around the digital mammography system’s dose‑tracking features and the dosimetry platform. The mammography unit is set to record glandular dose for every exposure and to generate cumulative dose summaries tied to each patient. Automated exposure control is calibrated to choose the Rh/Ag target–filter combination for breasts thicker than six centimeters, lowering dose by about twenty‑five percent compared with Rh/Rh while maintaining image contrast.

The dosimetry platform is linked to the mammography system and any hybrid imaging equipment to provide a unified view of radiation exposure. Action thresholds follow ACR and MQSA recommendations: a five‑year cumulative dose of thirty milligray triggers a review of the patient’s screening schedule. During stereotactic biopsy, the dose display is positioned within the radiologist’s direct line of sight, and an audible reminder sounds at one‑minute intervals after the first two minutes of fluoroscopy.

The dose‑management system uses automated outlier detection to flag exams that exceed the ninetieth percentile for glandular dose. For patients who undergo both screening mammography and fluoroscopic procedures, cumulative tracking ensures total exposure stays within safety limits. Quarterly reports are generated for the radiation‑safety officer, summarizing dose trends by technologist and by room to identify areas for optimization.